The p38 MAPK family consists of highly conserved proline-directed serine-threonine protein kinases that are activated in response to a number many growth factors, cytokines, and chemotactic substances, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), PDGF, TNF, interleukins, lipopolysaccharide (LPS) and formyl-methionyl-leucyl-phenylalanine (fMLP). It is well known that p38 is involved in inflammation, apoptosis, cardiomyocyte hypertrophy and cell differentiation.

The p38 MAPK family is composed of four proteins: p38α (encoded by the gene Mapk14), p38β (Mapk11), p38γ (Mapk12), and p38δ (Mapk13). Their coding genes have a distinct tissue distribution and they appear differentially expressed, being Mapk14 the most highly expressed. p38 MAPKs are substrates for three MAP2K (MKK6, MKK3, and MKK4). The contribution of each of these MAP2K to p38 MAPKs activation depends on the stimulus and the cell type. The MAP3Ks that lead to p38 MAPKs activation are ASK1, DLK1, TAK1, TAO1, TAO2, TPL2, MLK3, MEKK3, MEKK4, and ZAK1.
## p38 MAPK Inhibitors & Modulators

### p38 MAPK-IN-2

**Cat. No.:** HY-U00324  
**Bioactivity:** p38 MAPK-IN-2 is an inhibitor of p38 kinase.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
</tbody>
</table>

### Acumapimod

**Cat. No.:** HY-16715  
**Bioactivity:** Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC_{50} of less than 1 μM for p38α.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.14%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg</td>
</tr>
</tbody>
</table>

### AL 8697

**Cat. No.:** HY-108645  
**Bioactivity:** AL 8697 is a selective p38 MAPK inhibitor with IC_{50}s of 6 nM and 82 nM for p38α and p38β, respectively.\(^1\)

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.0%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg</td>
</tr>
</tbody>
</table>

### AZD7624

**Cat. No.:** HY-103672  
**Bioactivity:** AZD7624 is an inhaled p38 inhibitor, with potent anti-inflammatory activity.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>250 mg, 500 mg</td>
</tr>
</tbody>
</table>

### Bakuchiol

**Cat. No.:** HY-N0235  
**Bioactivity:** Bakuchiol is a phytoestrogen isolated from the seeds of Psoralea corylifolia L; has anti-tumor effects.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.25%</td>
<td>Phase 2</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg</td>
</tr>
</tbody>
</table>

### BMS-582949 hydrochloride

**Cat. No.:** HY-14305A  
**Bioactivity:** BMS-582949 hydrochloride is a novel highly selective p38α MAPK inhibitor, inhibits p38α with IC_{50} of 13 nM.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>98.82%</td>
<td>Phase 2</td>
<td>10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

### Dehydrocorydaline chloride

**Cat. No.:** HY-N0674A  
**Bioactivity:** Dehydrocorydaline chloride is an alkaloidal that has anti-inflammatory and anti-cancer activities. Dehydrocorydaline chloride can elevate p38 MAPK activation.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.95%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg</td>
</tr>
</tbody>
</table>

### Dilmapimod

**Cat. No.:** HY-10404  
**Bioactivity:** Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.56%</td>
<td>Phase 2</td>
<td>10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
</tbody>
</table>

### Doramapimod

**Cat. No.:** HY-10320  
**Bioactivity:** Doramapimod (BIRB 796) is a highly potent p38 MAPK inhibitor with an IC_{50} of 4 nM. It also inhibits B-Raf with an IC_{50} of 83 nM.

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.72%</td>
<td>Phase 2</td>
<td>10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg</td>
</tr>
</tbody>
</table>

### Ferulic acid methyl ester

**Cat. No.:** HY-W018643  
**Bioactivity:** Ferulic acid methyl ester (Methyl ferulate) is a derivative of ferulic acid, isolated from Stemona tuberosa, with anti-inflammatory and antioxidant properties.\(^1\) Ferulic acid methyl ester is a cell membrane and brain permeable compound, shows free radical scavenging ability.\(^2\)

<table>
<thead>
<tr>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.18%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 100 mg</td>
</tr>
</tbody>
</table>

---

\(^1\) Xie, J., et al. (2010).  
\(^2\) Li, Y., et al. (2011).
| **FR 167653**  
* (FR 167653 sulfate)  
| **Cat. No.: HY-18754A**  
| **Bioactivity:** FR-167653 is a selective p38 MAPK inhibitor.  
| **Purity:** >98%  
| **Clinical Data:** No Development Reported  
| **Size:** 250 mg, 500 mg  

| **FR 167653 free base**  
| **Cat. No.: HY-18754**  
| **Bioactivity:** FR-167653 is a selective p38 MAPK inhibitor.  
| **Purity:** >98%  
| **Clinical Data:** No Development Reported  
| **Size:** 250 mg, 500 mg  

| **ITX5061**  
| **Cat. No.: HY-19900**  
| **Bioactivity:** ITX5061 is a type II inhibitor of p38 MAPK and also an antagonist of scavenger receptor B1 (SR-B1).  
| **Purity:** 98.07%  
| **Clinical Data:** No Development Reported  
| **Size:** 10mM x 1mL in DMSO, 
1 mg, 5 mg, 10 mg  

| **Losmapimod**  
*(GSK-AHAB, GW856553X; SB856553)*  
| **Cat. No.: HY-10402**  
| **Bioactivity:** Losmapimod is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38α and p38β, respectively.  
| **Purity:** 97.08%  
| **Clinical Data:** Phase 3  
| **Size:** 10mM x 1mL in DMSO, 
10 mg, 50 mg  

| **MAPK13-IN-1**  
| **Cat. No.: HY-18850**  
| **Bioactivity:** MAPK13-IN-1 is a MAPK13 (p38δ) inhibitor, with an ICS0 of 620 nM.  
| **Purity:** >98%  
| **Clinical Data:** No Development Reported  
| **Size:** 250 mg, 500 mg  

| **MW-155**  
*(MW01-18-150SRM)*  
| **Cat. No.: HY-120111**  
| **Bioactivity:** MW150 (MW01-18-150SRM) is a selective inhibitor of p38αMAPK isoform with a K_i of 101 nM [1].  
| **Purity:** >98%  
| **Clinical Data:** No Development Reported  
| **Size:** 250 mg, 500 mg  

| **MW-150 dihydrochloride dihydrate**  
*(MW01-18-150SRM dihydrochloride dihydrate)*  
| **Cat. No.: HY-120111B**  
| **Bioactivity:** MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective inhibitor of p38αMAPK isoform with a K_i of 101 nM [1].  
| **Purity:** >98%  
| **Clinical Data:** No Development Reported  
| **Size:** 5 mg, 10 mg, 50 mg, 100 mg  

| **MW-150 hydrochloride**  
*(MW01-18-150SRM hydrochloride)*  
| **Cat. No.: HY-120111A**  
| **Bioactivity:** MW-150 hydrochloride (MW01-18-150SRM hydrochloride) is a selective inhibitor of p38αMAPK isoform with a K_i of 101 nM [1].  
| **Purity:** >98%  
| **Clinical Data:** No Development Reported  
| **Size:** 250 mg, 500 mg  

| **Neflamapimod**  
*(VX-745)*  
| **Cat. No.: HY-10328**  
| **Bioactivity:** Neflamapimod (VX-745) is a potent and selective inhibitor of p38α, and possesses anti-inflammatory activity.  
| **Purity:** 98.74%  
| **Clinical Data:** Phase 2  
| **Size:** 10mM x 1mL in DMSO, 
10 mg, 50 mg  

| **p38 MAPK-IN-1**  
| **Cat. No.: HY-12839**  
| **Bioactivity:** p38 MAPK-IN-1 is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM, shows sustained levels, low clearance and good bioavailability.  
| **Purity:** 99.90%  
| **Clinical Data:** No Development Reported  
| **Size:** 10mM x 1mL in DMSO, 
5 mg, 10 mg, 50 mg, 100 mg  

---

www.MedChemExpress.com
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Bioactivity</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>p38-α MAPK-IN-1</td>
<td>HY-18874</td>
<td>p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC₅₀ of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay.</td>
<td>99.92%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>p38α inhibitor 1</td>
<td>HY-114423</td>
<td>p38α inhibitor 1 is a p38α inhibitor extracted from patent WO 2008076265 A1.</td>
<td>98.70%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Pamapimod</td>
<td>HY-10405</td>
<td>Pamapimod is a novel p38 mitogen-activated protein kinase inhibitor. Pamapimod inhibited p38α and p38β enzymatic activity, with IC₅₀ values of 0.014 ± 0.002 and 0.48 ± 0.04 μM, respectively. Pamapimod is p38 inhibitor with IC₅₀ of 0.06μM in THP-1 cell. IC₅₀: 0.014 ± 0.002 and 0.48 ± 0.04...</td>
<td>99.86%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg</td>
</tr>
<tr>
<td>PD 169316</td>
<td>HY-10578</td>
<td>PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor, with IC₅₀ of 89 nM.</td>
<td>98.33%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 10 mg, 50 mg</td>
</tr>
<tr>
<td>Pexmetinib</td>
<td>HY-16782</td>
<td>Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC₅₀ of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.</td>
<td>99.90%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>PH-797804</td>
<td>HY-10403</td>
<td>PH-797804 is a novel pyridinone inhibitor of p38α with IC₅₀ of 26 nM; 4-fold more selective versus p38β and does not inhibit JNK2, IC₅₀ value: 26 nM [1] Target: p38αMAPK in vitro: PH-797804 blocks LPS-induced TNF-α production and p38 kinase activity in the human monocytic U937 cell line, with...</td>
<td>98.59%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>R1487 Hydrochloride</td>
<td>HY-14975</td>
<td>R1487 Hydrochloride is highly potent and highly selective inhibitors of p38α. Target: p38α. R1487 (Hydrochloride) potently inhibits cytokine production in a variety of in vitro and in vivo models.[1] R1487 (Hydrochloride) inhibits production of TNFR by human monocytes (THP-1) and...</td>
<td>98.68%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Ralimetinib</td>
<td>HY-13241A</td>
<td>Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC₅₀ of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or...</td>
<td>99.98%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Ralimetinib dimesylate</td>
<td>HY-13241</td>
<td>Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC₅₀ of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or...</td>
<td>99.98%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>SB 202190</td>
<td>HY-10295</td>
<td>SB 202190 is a cell-permeable p38 MAP kinase inhibitor with IC₅₀ of 50 nM and 100 nM for p38 and p38β2, respectively.</td>
<td>99.89%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg</td>
</tr>
</tbody>
</table>
SB 203580 (RWJ 64809)  
**Cat. No.: HY-10256**

**Bioactivity:** SB 203580 (RWJ 64809) is a widely used p38 MAPK inhibitor with an IC₅₀ of 0.3-0.5 μM. SB 203580 (RWJ 64809) shows more than 100-fold selectivity over Akt (PKB), LCK, and GSK-3β.

**Purity:** 99.92%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg

---

SB 203580 hydrochloride (RWJ 64809 hydrochloride)  
**Cat. No.: HY-10256A**

**Bioactivity:** SB 203580 hydrochloride (RWJ 64809 hydrochloride) is a widely used p38 MAPK inhibitor with an IC₅₀ of 0.3-0.5 μM. SB 203580 hydrochloride shows more than 100-fold selectivity over Akt (PKB), LCK, and GSK-3β.

**Purity:** 99.71%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg

---

SB 239063  
**Cat. No.: HY-11068**

**Bioactivity:** SB 239063 is a potent and selective p38 MAPK inhibitor (IC₅₀ = 44 nM for p38α). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. IC₅₀ value: 44 nM (p38α) Target: p38 MAPK SB 239063 reduces inflammatory cytokine production and is...  

**Purity:** 99.53%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

---

SB 242235  
**Cat. No.: HY-18306**

**Bioactivity:** SB-242235 is a potent and selective p38 MAP kinase inhibitor with an IC₅₀ of 1.0 μM. IC₅₀ Value: 1.0 μM [1] Target: p38 MAPK in vitro: SB 242235 inhibited intracellular p38 activity, human chondrocytes were treated with different doses of SB 242235 prior to stimulation with IL-1β for 15 min. MAPKAP-K2...  

**Purity:** 99.63%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

SD 0006 (SD-06)  
**Cat. No.: HY-11087**

**Bioactivity:** SD 0006 (SD-06) is a p38 MAP kinase inhibitor; inhibits p38α with an IC₅₀ value of 170 nM and inhibits LPS-stimulated TNF-release in rats (83% inhibition at 1mg/kg, po).  

**Purity:** 98.0%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg

---

SJFα  
**Cat. No.: HY-114404**

**Bioactivity:** SJFα is a 13-atom linker PROTAC. SJFα degrades p38α with a DC₅₀ of 7.16nM, but is far less effective at degrading p38β (DC₅₀=299nM) and does not degrade the other p38 isoforms (B and γ) at concentrations up to 2.5μM [1].  

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 500 mg, 250 mg

---

SJFδ  
**Cat. No.: HY-114405**

**Bioactivity:** SJFδ is a 10-atom linker PROTAC. SJFδ degrades p38δ with a DC₅₀ of 46.17nM, but does not degrade p38α, p38β, or p38γ DC₅₀. [1]  

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 250 mg, 500 mg

---

Skatole (3-Methylindole; 3-Methyl-1H-indole)  
**Cat. No.: HY-W007355**

**Bioactivity:** Skatole is produced by intestinal bacteria, regulates intestinal epithelial cellular functions through activating aryl hydrocarbon receptors and p38 [1].  

**Purity:** 98.0%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 100 mg

---

Skepinone-L (CBS3830)  
**Cat. No.: HY-15300**

**Bioactivity:** Skepinone-L (CBS3830) is a selective p38 mitogen-activated protein kinase inhibitor.  

**Purity:** 99.63%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

---

SKF-86002  
**Cat. No.: HY-12511**

**Bioactivity:** SKF-86002 is a potent inhibitor of p38 MAP kinase with IC₅₀ of 0.5-1 μM; inhibits LPS-induced IL-1 and TNF-α production in human monocytes (IC₅₀ = 1 μM).  

**Purity:** 99.51%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg
**TA-01**  
**Cat. No.: HY-100114**

**Bioactivity:** TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC_{50} of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively.

**Purity:** 99.75%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

---

**TA-02**  
**Cat. No.: HY-100115**

**Bioactivity:** TA-02 is a p38 MAPK inhibitor with IC_{50} of 20 nM.

**Purity:** 99.30%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

---

**TAK-715**  
**Cat. No.: HY-10456**

**Bioactivity:** TAK-715 is a p38 MAPK inhibitor for p38α with IC_{50} of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or Tak1. IC_{50} value: 7.1 nM [1] Target: p38α MAPK in vitro: TAK 715 inhibits LPS-stimulated release of TNF-alpha from THP-1 with IC_{50} of 48...

**Purity:** 99.93%

**Clinical Data:** Phase 2

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

---

**Talmapimod**  
**(SCIO-469)**  
**Cat. No.: HY-10406**

**Bioactivity:** Talmapimod (SCIO-469) is a selective ATP-competitive p38 inhibitor with IC_{50} of 9 nM for p38α.

**Purity:** 98.73%

**Clinical Data:** Phase 2

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg

---

**Tat-NR2B9c**  
**Cat. No.: HY-P0117**

**Bioactivity:** Tat-NR2B9c is a 20-aa peptide, which acts as a postsynaptic density-95 (PSD-95) inhibitor, with an EC_{50} of 6.7 nM for PSD-95d2 (PSD-95 PDZ domain 2), and 670 nM for PSD-95d1; Tat-NR2B9c also reduces NMDA-induced p38 activation, and possesses neuroprotective efficacy.

**Purity:** 98.22%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in Water, 1 mg, 5 mg, 10 mg, 25 mg

---

**Tat-NR2B9c TFA**  
**Cat. No.: HY-P0117A**

**Bioactivity:** Tat-NR2B9c (TFA) is a 20-aa peptide, which acts as a postsynaptic density-95 (PSD-95) inhibitor, with an EC_{50} of 6.7 nM for PSD-95d2 (PSD-95 PDZ domain 2), and 670 nM for PSD-95d1 [1]. Tat-NR2B9c also reduces NMDA-induced p38 activation.

**Purity:** 98.99%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in Water, 1 mg, 5 mg, 10 mg, 25 mg

---

**UM-164**  
**(DAS-DFGO-II)**  
**Cat. No.: HY-112182**

**Bioactivity:** UM-164 (DAS-DFGO-II) is a highly potent inhibitor of c-Src with a K_{d} of 2.7 nM. UM-164 also potently inhibits p38α and p38β.

**Purity:** 99.08%

**Clinical Data:** No Development Reported

**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**VX-702**  
**Cat. No.: HY-10401**

**Bioactivity:** VX-702 is a highly selective inhibitor of p38α MAPK (IC_{50} = 4 - 20 nM), 14-fold higher potency against the p38α versus p38β. IC_{50} value: 4 - 20 nM [1] Target: p38α MAPK in vitro: Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC_{50} 4 to 20 nM) induced by platelet...

**Purity:** 99.75%

**Clinical Data:** Phase 2

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg